Sandra Levy
ARTICLES BY THIS AUTHOR
- 1/2/2020
Daiichi Sankyo obtains FDA approval for Enhertu
Daiichi Sankyo's Enhertu provides a new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. - 1/1/2020
Lannett gets FDA nod for generic butalbital, acetaminophen and caffeine capsules
The two dosage strengths of BAC capsules have a combined estimated market value of approximately $68.6 million for the 12 months ended October 2019. - 1/1/2020
Dr. Reddy's intros generic Nitropress
The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019. - 1/1/2020
Micro Labs, Mylan get FDA OK for generic Eliquis
The generic is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. - 1/1/2020
Allergan gets FDA OK for Ubrelvy
Ubrelvy is the first and only oral calcitonin gene-related peptide receptor antagonist for the treatment of migraine attacks once they start. - 12/29/2019
FDA approves expanded indication for Amarin’s Vascepa
Vascepa was originally approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. - 12/29/2019
Ortho Dermatologics gets FDA green light for Arazlo
Arazlo is the first FDA approved tazarotene acne treatment in a lotion formulation. - 12/26/2019
Lupin gets FDA OK for generic Myfortic, launches generic Hectorol
Mycophenolic acid delayed-release tablets and doxercalciferol injection had a market value of roughly $174 million and $132 million, respectively. - 12/26/2019
Amneal names 3 executives to its board of directors
Jeff George, John Kiely and Shlomo Yanai have been appointed to Amneal’s board of directors. - 12/25/2019
E5 Pharma launches generic Proglycem
e5 Pharma's diazoxide oral suspension is the first generic of Proglycem.
